Synthesis of glycoconjugate carbonic anhydrase inhibitors by ruthenium-catalysed azide-alkyne 1,3-dipolar cycloaddition

Bioorg Med Chem Lett. 2011 Oct 15;21(20):6058-61. doi: 10.1016/j.bmcl.2011.08.066. Epub 2011 Aug 22.

Abstract

Carbonic anhydrase IX (CA IX) is a recently validated target for the development of new cancer therapies. In this Letter we describe the synthesis and CA inhibition of a novel series of carbohydrate-based 1,5-disubstituted-1,2,3-triazole benzenesulfonamides. The key step of our synthesis is the regioselective Huisgen's 1,3-dipolar cycloaddition reaction (1,3-DCR) from carbohydrate azide substrates and 4-ethynylbenzenesulfonamide using a ruthenium-catalysed azide-alkyne cycloaddition (RuAAC). Our findings identified a number of triazole inhibitors (compounds 18, 19, 21-23, and 26) that block CA IX activity with inhibition constants less than 10 nM. One inhibitor (compound 17) possessed very good selectivity for CA IX over off-target CAs. These CA inhibitors have developmental potential to selectively target cancer cells, leading to cell death.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkynes / chemical synthesis
  • Alkynes / chemistry*
  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Azides / chemical synthesis
  • Azides / chemistry*
  • Carbonic Anhydrase Inhibitors / chemical synthesis*
  • Carbonic Anhydrase Inhibitors / chemistry
  • Carbonic Anhydrase Inhibitors / pharmacology
  • Carbonic Anhydrases / metabolism
  • Catalysis
  • Cell Line, Tumor
  • Cyclization
  • Glycoconjugates / chemical synthesis*
  • Glycoconjugates / chemistry
  • Glycoconjugates / pharmacology
  • Humans
  • Neoplasms / drug therapy
  • Ruthenium / chemistry*

Substances

  • Alkynes
  • Antineoplastic Agents
  • Azides
  • Carbonic Anhydrase Inhibitors
  • Glycoconjugates
  • Ruthenium
  • Carbonic Anhydrases